AtaiBeckley Inc. Form 4 Filings

AtaiBeckley Inc. (ATAI) completed a merger on September 11, 2026 in which Albali Acquisition Corporation, a subsidiary of Eli Lilly and Company, merged with and into AtaiBeckley, leaving AtaiBeckley as a wholly owned subsidiary of Eli Lilly. At the effective time of the merger, each share of AtaiBeckley common stock converted into the right to receive $6.75 in cash per share plus one contingent value right (CVR) per share, representing the right to receive up to an additional $2.50 in cash per CVR if specified clinical and regulatory milestones are achieved. In connection with this transaction, Chief Medical Officer Craig Kevin James reported dispositions to the issuer of all his directly held common stock and equity awards, including multiple stock option grants and 150,000 restricted stock units, which were cancelled and converted into cash based on the $6.75 value and, for options, the excess of $6.75 over the exercise price, plus one CVR for each underlying share.

AtaiBeckley Inc. (ATAI) completed a merger in which Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged into AtaiBeckley on September 11, 2026, with AtaiBeckley surviving as a wholly owned subsidiary of Eli Lilly. Chief Accounting Officer Anne Nagengast reported dispositions to the issuer of common stock, stock options and restricted stock units at the merger’s effective time. Each common share converted into the right to receive $6.75 in cash plus one contingent value right (CVR) for up to an additional $2.50 in cash per CVR upon specified milestones. Each outstanding stock option and RSU was cancelled and converted into cash based on the $6.75 reference price plus one CVR per underlying share, so these Form 4 entries reflect automatic cancellation and cash-out of equity awards, not open-market trading, and no Rule 10b5-1 plan is reported.

AtaiBeckley Inc. (ATAI) completed a merger on September 11, 2026 in which Albali Acquisition Corporation merged into the company, leaving it as a wholly owned subsidiary of Eli Lilly and Company. At the effective time, each common share converted into the right to receive $6.75 in cash plus one contingent value right (CVR) per share, with each CVR representing up to an additional $2.50 in cash upon specified clinical and regulatory milestones. On the same date, Chief Legal and Business Officer Barrett Christopher Ryan Cave reported dispositions to the issuer of his common stock, stock options, and restricted stock units, which were cancelled and converted into cash consideration and CVRs in connection with the merger; no Rule 10b5-1 trading plan is reported.

AtaiBeckley Inc. (symbol: ATAI) is the issuer of record for a Form 4 filing submitted to the SEC. Short Glenn Frank reported disposition transactions in this Form 4 filing.

AtaiBeckley Inc. (ATAI) reported that Chief Scientific Officer Short Glenn Frank had his equity in the company cancelled and cashed out on September 11, 2026 in connection with the closing of a merger with a subsidiary of Eli Lilly and Company. At the effective time, his 42,333 shares of common stock were converted into the right to receive $6.75 per share in cash plus one contingent value right (CVR) per share, with each CVR representing up to an additional $2.50 in cash upon achievement of specified milestones. Multiple stock option grants and 150,000 restricted stock units were similarly cancelled and converted into cash based on the $6.75 reference price and into one CVR for each underlying share, so that, after these transactions, he no longer directly held common stock or RSUs.

AtaiBeckley Inc. (ATAI) reported that its Chief Financial Officer, Michael E. Faerm, disposed of all reported equity awards in connection with the closing of a merger in which AtaiBeckley became a wholly owned subsidiary of Eli Lilly and Company. On September 11, 2026, an Albali Acquisition Corporation subsidiary of Eli Lilly merged with AtaiBeckley, with AtaiBeckley surviving as a subsidiary.

At the merger’s effective time, a stock option covering 1,275,000 shares of common stock with a $4.06 exercise price and expiring March 11, 2036 was cancelled and converted into the right to receive cash equal to the number of shares multiplied by the excess of $6.75 over the exercise price per share, plus one contingent value right (CVR) for each underlying share. In addition, 285,000 restricted stock units were cancelled and converted into the right to receive cash equal to the number of shares multiplied by $6.75, plus one CVR per underlying share. Each CVR represents the right to receive up to $2.50 in cash upon achievement, if any, of specified clinical and regulatory milestones. Following these cancellations and conversions, the Form 4 shows no remaining holdings for these awards, and no Rule 10b5‑1 trading plan is reported.

AtaiBeckley Inc. (ATAI) director Laurent Fischer reported issuer dispositions of three stock option awards on September 11, 2026 in connection with the completion of a merger in which AtaiBeckley became a wholly owned subsidiary of Eli Lilly and Company. At the merger’s effective time, each affected option was automatically cancelled and converted into the right to receive cash plus a contingent value right. The cancelled options covered 206,000 shares at a $1.34 exercise price expiring June 13, 2034, 103,000 shares at $2.25 expiring June 26, 2035, and 121,968 shares at $4.50 expiring June 4, 2036.

For each share subject to these options, the holder became entitled to a cash payment equal to the product of the number of shares and the excess of $6.75 over the applicable exercise price, plus one contingent value right per share representing the right to receive up to an additional $2.50 in cash upon specified clinical and regulatory milestones, in each case subject to tax withholding. No Rule 10b5-1 trading plan is reported for these transactions.

AtaiBeckley Inc. (ATAI) director John Francis Hoffman reported the disposition to the issuer of stock options in connection with the company’s merger with Eli Lilly and Company. On September 11, 2026, a total of 206,000 options at a $2.25 exercise price and 121,968 options at a $4.50 exercise price were cancelled at the Merger’s Effective Time and converted into rights to receive cash plus one contingent value right per underlying share, consistent with the merger agreement terms.

AtaiBeckley Inc. (ATAI) reports that director Amir H. Kalali disposed of all reported equity positions in connection with the closing of a merger with Eli Lilly and Company. On September 11, 2026, Albali Acquisition Corporation merged into AtaiBeckley, which became a wholly owned subsidiary of Eli Lilly.

At the merger’s effective time, 4,666 shares of common stock held by the reporting person were converted into the right to receive $6.75 per share in cash plus one contingent value right (CVR) per share, with each CVR representing up to $2.50 in additional cash upon specified clinical and regulatory milestones. In parallel, outstanding stock options covering multiple blocks of shares at exercise prices ranging from $1.34 to $4.50 were cancelled and converted into cash equal to the in-the-money value based on the $6.75 per-share merger price, plus one CVR for each underlying share.

AtaiBeckley Inc. (ATAI) completed a merger in which Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged into AtaiBeckley on September 11, 2026, making AtaiBeckley a wholly owned subsidiary of Eli Lilly. Director Andrea Heslin Smiley reported dispositions to the issuer of multiple stock option awards and 4,666 shares of common stock. At the effective time of the merger, each common share converted into the right to receive $6.75 in cash per share plus one contingent value right (CVR) per share, and each outstanding company stock option was cancelled and converted into cash based on the excess of $6.75 over the option’s exercise price per share plus one CVR for each underlying share.

AtaiBeckley Inc. (ATAI) director Scott Braunstein reported the disposition of four stock option grants in connection with the closing of a merger in which AtaiBeckley became a wholly owned subsidiary of Eli Lilly and Company. On September 11, 2026, at the merger’s Effective Time, each covered option was automatically cancelled and converted into the right to receive cash plus a contingent value right.

The cash portion for each option equals the number of underlying common shares multiplied by the excess of $6.75 over the option’s exercise price per share, less applicable tax withholdings, and holders also receive one contingent value right (CVR) per share that can pay up to $2.50 in cash upon achievement of specified clinical and regulatory milestones. No Rule 10b5-1 trading plan is reported for these transactions.

AtaiBeckley Inc. (ATAI) completed a merger in which Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged into AtaiBeckley on September 11, 2026, making AtaiBeckley a wholly owned subsidiary of Eli Lilly. Co-founder, chief executive officer and director Rao Srinivas reported dispositions of common stock, options and RSUs to the issuer at the merger’s effective time, as all such equity awards were automatically cancelled and converted into rights to receive $6.75 in cash per share plus one contingent value right (CVR) per share or per underlying share, with each CVR representing up to an additional $2.50 in cash upon achievement of specified clinical and regulatory milestones. No Rule 10b5-1 trading plan is reported.

AtaiBeckley Inc. (ATAI) director Robert Hershberg reported issuer dispositions of several stock option awards on September 11, 2026, in connection with the completion of the company’s merger with a subsidiary of Eli Lilly and Company. At the merger’s effective time, these options were cancelled and converted into cash and contingent value rights.

Each cancelled option became the right to receive cash based on the $6.75 per-share merger price above its exercise price, plus one contingent value right per underlying share, which may pay up to an additional $2.50 in cash upon specified clinical and regulatory milestones.

AtaiBeckley Inc. (ATAI) director Sabrina Martucci Johnson reported the disposition of several stock option awards on September 11, 2026, in connection with the merger of AtaiBeckley with a subsidiary of Eli Lilly and Company. At the merger’s Effective Time, each reported option was cancelled and converted into cash plus one contingent value right (CVR) per underlying common share, based on a cash price of $6.75 per share minus the applicable exercise price and potential additional CVR payments of up to $2.50 per share upon specified clinical and regulatory milestones. No Rule 10b5-1 trading plan is reported for these transactions.

AtaiBeckley Inc. (ATAI) reports that, in connection with its merger into a wholly owned subsidiary of Eli Lilly and Company on September 11, 2026, all common shares and stock options reported by director and ten percent owner Christian Angermayer and related Apeiron entities were disposed of and now show zero ATAI common stock holdings.

Each share of common stock converted into the right to receive $6.75 in cash plus one contingent value right (CVR) per share, and each outstanding stock option was cancelled and converted into cash based on $6.75 minus the option’s exercise price per underlying share plus one CVR per underlying share. No Rule 10b5-1 trading plan is reported.

AtaiBeckley Inc. director Robert Hershberg reported option exercises and share sales. On July 7, 2026, he exercised stock options to acquire 100,000 shares of common stock at $1.35 per share and sold 100,000 shares at a weighted average price of $4.96.

The sales occurred in multiple trades between $4.90 and $5.08 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 100,000 shares of AtaiBeckley common stock.

AtaiBeckley Inc.’s Chief Medical Officer, Craig Kevin James, reported an option exercise-and-sale transaction in company stock. On June 25, 2026, he exercised stock options covering 42,579 shares of common stock at strike prices of $1.18 and $1.50 per share and sold 42,579 shares in open-market transactions at a weighted average price of $4.51 per share. The filing states these option exercises and sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025. After the transactions, he held 8,437 shares of common stock directly and continued to hold stock options, including 28,608 options at an exercise price of $1.18 expiring on March 14, 2033 and 673,808 options at an exercise price of $1.50 expiring on March 3, 2035.

AtaiBeckley Inc. Chief Operating Officer Gerd Kochendoerfer reported an options exercise and share sale involving the company’s common stock. On June 26, 2026, he sold 50,000 shares in an open-market transaction at $5.00 per share and exercised stock options to acquire 50,000 shares at $1.60 per share.

The filing indicates these option exercises and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2026, which means the trades were scheduled in advance. Following the transactions, Kochendoerfer directly holds 50,000 common shares and 1,400,000 stock options that remain outstanding, according to the reported post-transaction balances.

AtaiBeckley Inc. director and 10% owner Christian Angermayer received a grant of stock options covering 121,968 shares of common stock at an exercise price of $4.50 per share. These options expire on June 4, 2036.

The options will vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, provided Angermayer continues to serve on the company's board of directors through the applicable vesting date. Following this grant, his reported option holdings from this award total 121,968 shares.

AtaiBeckley Inc. director Scott Braunstein received two stock option awards. On June 4, 2026, he was granted options covering 86,095 and 121,968 shares of common stock at an exercise price of $4.50 per share, expiring on June 4, 2036.

The options were granted as compensation and not through open-market purchases. According to the footnote, each option will vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, provided he continues to serve on the board through the vesting date.

AtaiBeckley Inc. director Laurent Fischer received a stock option grant as equity compensation. The award covers 121,968 shares of common stock at an exercise price of $4.50 per share, expiring on June 4, 2036.

The option will vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to Fischer's continued service on the board of directors through the vesting date. Following this grant, he holds stock options for 121,968 underlying shares directly.

AtaiBeckley Inc. director Robert Hershberg received a grant of stock options covering 121,968 shares of common stock. The options have an exercise price of $4.5000 per share and expire on June 4, 2036.

The award vests on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to his continued service on the board through the vesting date. Following this grant, he holds 121,968 stock options directly.

AtaiBeckley Inc. director John Francis Hoffman received a grant of stock options covering 121,968 shares of Common Stock. The options have an exercise price of $4.50 per share and expire on June 4, 2036.

The option award vests on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to his continued service on the board of directors through the vesting date. Following this grant, Hoffman holds stock options for 121,968 underlying shares directly.

AtaiBeckley Inc. director Amir H Kalali received a stock option grant as part of his board compensation. The option covers 121,968 shares of common stock with a $4.50 exercise price and expires on June 4, 2036. It vests on the earlier of the day before the company’s next annual meeting or June 4, 2027, subject to his continued service on the board.

AtaiBeckley Inc. director Andrea Heslin Smiley received a grant of stock options covering 121,968 shares of common stock at an exercise price of $4.50 per share. These options vest on the earlier of the day before the company’s next annual meeting or June 4, 2027, contingent on continued board service.

AtaiBeckley Inc. director Sabrina Martucci Johnson received a grant of stock options covering 121,968 shares of common stock at an exercise price of $4.50 per share. The options expire on June 4, 2036 and vest on the earlier of the day before the company’s next annual meeting or June 4, 2027, subject to continued board service.

AtaiBeckley Inc. Chief Medical Officer Craig Kevin James executed a pre-planned option exercise-and-sale transaction involving company common stock. On the reported date, he sold 42,579 shares of common stock in an open-market sale at $5.00 per share and exercised stock options covering a total of 42,579 shares at exercise prices of $1.84 and $1.50 per share. The filing states that these option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on December 19, 2025, indicating the trades were pre-arranged rather than timed discretionarily.

AtaiBeckley Inc. director and ten percent owner Christian Angermayer exercised stock options to acquire a total of 559,232 shares of common stock on April 8, 2026. The options were exercised at prices of $1.34, $1.64 and $1.88 per share.

Following these exercises, Angermayer holds 559,232 ATAI shares directly, in addition to substantial indirect holdings, including 1,799,302 shares held by Apeiron Presight Capital Fund II, L.P. and 53,412,414 shares held by Apeiron Investment Group Ltd. The filing shows option exercises only, with no reported open-market sales.